Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
- PMID: 35052811
- PMCID: PMC8773533
- DOI: 10.3390/biomedicines10010131
Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
Abstract
Background: Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women's reproductive period of life. The presence of nonalcoholic fatty liver disease NAFLD, one of the leading causes of chronic liver disease in the Western world, is increased in women with PCOS. This review aims to present current knowledge in epidemiology, pathophysiology, diagnostics, and treatment of NAFLD in PCOS with an emphasis on the molecular basis of development of NAFLD in PCOS women. Methods: Authors investigated the available data on PCOS and NAFLD by a MEDLINE and Pub Med search during the years 1990-2021 using a combination of keywords such as "PCOS", "NAFLD", "steatohepatitis", "insulin resistance", "hyperandrogenaemia", "inflammation", "adipose tissue", and "obesity". Peer-reviewed articles regarding NAFLD and PCOS were included in this manuscript. Additional articles were identified from the references of relevant papers. Results: PCOS and NAFLD are multifactorial diseases, The development of NAFLD in PCOS women is linked to insulin resistance, hyperandrogenemia, obesity, adipose tissue dysfunction, and inflammation. There is the possible role of the gut microbiome, mitochondrial dysfunction, and endocannabinoid system in the maintenance of NAFLD in PCOS women. Conclusions: There is a need for further investigation about the mechanism of the development of NAFLD in PCOS women. New data about the molecular basis of development of NAFLD in PCOS integrated with epidemiological and clinical information could influence the evolution of new diagnostic and therapeutic approaches of NAFLD in PCOS.
Keywords: NAFLD; PCOS; hyperandrogenemia; insulin resistance; obesity.
Conflict of interest statement
Authors disclose no conflict of interest.
Figures

Similar articles
-
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.Diabetes Metab Syndr Obes. 2022 Apr 24;15:1281-1291. doi: 10.2147/DMSO.S362424. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 35494531 Free PMC article. Review.
-
Nonalcoholic fatty liver disease and polycystic ovary syndrome.World J Gastroenterol. 2014 Jul 14;20(26):8351-63. doi: 10.3748/wjg.v20.i26.8351. World J Gastroenterol. 2014. PMID: 25024594 Free PMC article. Review.
-
Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?Endocrine. 2016 Feb;51(2):211-21. doi: 10.1007/s12020-015-0640-8. Epub 2015 May 30. Endocrine. 2016. PMID: 26024975 Review.
-
Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.Curr Pharm Des. 2018;24(38):4593-4597. doi: 10.2174/1381612825666190117100751. Curr Pharm Des. 2018. PMID: 30652641 Review.
-
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.Endocrine. 2020 Jan;67(1):1-8. doi: 10.1007/s12020-019-02085-7. Epub 2019 Sep 19. Endocrine. 2020. PMID: 31538291 Review.
Cited by
-
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas). 2024 Dec 30;61(1):38. doi: 10.3390/medicina61010038. Medicina (Kaunas). 2024. PMID: 39859020 Free PMC article. Review.
-
Elevated Triglyceride-Glucose Index Is Associated With Insulin Resistance, Metabolic Syndrome Components, Nonalcoholic Fatty Liver Disease, and Adverse Pregnancy Outcomes in Chinese Women With Polycystic Ovary Syndrome.Clin Endocrinol (Oxf). 2025 Sep;103(3):317-326. doi: 10.1111/cen.15252. Epub 2025 Apr 29. Clin Endocrinol (Oxf). 2025. PMID: 40298068 Free PMC article.
-
Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review.J Diabetes Metab Disord. 2023 Sep 8;22(2):1083-1094. doi: 10.1007/s40200-023-01293-3. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975107 Free PMC article. Review.
-
Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment.J Ovarian Res. 2023 Jan 11;16(1):9. doi: 10.1186/s13048-022-01091-0. J Ovarian Res. 2023. PMID: 36631836 Free PMC article. Review.
-
Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones.Front Endocrinol (Lausanne). 2022 Nov 7;13:1032361. doi: 10.3389/fendo.2022.1032361. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36419770 Free PMC article.
References
-
- Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J. Clin. Endocrinol. Metab. 1998;83:3078–3082. doi: 10.1210/jc.83.9.3078. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources